GSK plc

A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday.The initial…

Budrul Chukrut | Lightrocket | Getty ImagesGlaxoSmithKline CEO Emma Walmsley on Wednesday said she expects uptake for the company's new RSV vaccine to start off slower than it did for its…

Respiratory syncytial virus vial.Manjurul | Istock | Getty ImagesThe Centers for Disease Control and Prevention on Thursday recommended that adults ages 60 and above receive a single dose of…

Respiratory syncytial virus vial.Manjurul | Istock | Getty ImagesVaccinating one million adults ages 65 and above with a single RSV shot from Pfizer or GSK may prevent thousands of…

A health worker prepares a flu vaccine shot before administering it to a local resident in Los Angeles, the United States, on Dec. 17, 2022.Xinhua News Agency | Getty ImagesAn advisory…

Respiratory syncytial virus viral vaccine under research.Hailshadow | Istock | Getty ImagesGlaxoSmithKline on Wednesday said its vaccine to protect adults ages 60 and older from respiratory…

Respiratory syncytial virus - viral vaccine under researchHailshadow | Istock | Getty ImagesPfizer's vaccine that protects adults ages 60 and older from respiratory syncytial virus was…

Luis Alvarez | Digitalvision | Getty ImagesThe Food and Drug Administration on Wednesday approved a vaccine made by Pfizer that protects adults ages 60 and older from respiratory syncytial…

Respiratory syncytial virus - viral vaccine under researchHailshadow | Istock | Getty ImagesThe Food and Drug Administration's independent panel of advisors on Thursday recommended full…

Blood sample for respiratory syncytial virus (RSV) testJarun011 | Istock | Getty ImagesU.S. Food and Drug Administration staff on Tuesday said Pfizer's vaccine that protects infants from…